Case: Patents/Subject Matter (D. Del.)

Sept. 23, 2021, 3:22 PM

A federal district court in Delaware granted Elysium Health’s motion for summary judgment of invalidity in ChromaDex Inc.'s action for infringement of its patents for nucleotide sequences coding muscle specific integrin binding protein for use as a tool in targeting cancer cells for destruction and nicotinamide riboside kinase compositions and methods for using the same. The court ruled that the asserted claims are directed to a natural phenomenon, and that they don’t contain an inventive concept sufficient to transform the claimed concept into a patent-eligible application.

To read the full article log in. To learn more about a subscription click here.